Cargando…

2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes

OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Andrea, Mathews, Clayton, Haller, Michael, Brusko, Todd, Atkinson, Mark, Flynn, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798906/
http://dx.doi.org/10.1017/cts.2017.136
_version_ 1783460161138982912
author Lin, Andrea
Mathews, Clayton
Haller, Michael
Brusko, Todd
Atkinson, Mark
Flynn, Ryan
author_facet Lin, Andrea
Mathews, Clayton
Haller, Michael
Brusko, Todd
Atkinson, Mark
Flynn, Ryan
author_sort Lin, Andrea
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis of phase 1 peripheral blood samples treatment of nonobese diabetic mouse with ATG and GCSF and flow cytometry analysis of immune organs (spleen, lymph nodes, blood, bone marrow). RESULTS/ANTICIPATED RESULTS: Changes in both innate and adaptive immune cell subsets including plasmacytoid dendritic cells, naive, memory, effector CD4+ and CD8+ T-cells, and CD4+ T-regulatory cells and CD8+ T-regulatory cells DISCUSSION/SIGNIFICANCE OF IMPACT: Understanding of immune cell targets for immunotherapy in new-onset type 1 diabetes patients.
format Online
Article
Text
id pubmed-6798906
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67989062019-10-28 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes Lin, Andrea Mathews, Clayton Haller, Michael Brusko, Todd Atkinson, Mark Flynn, Ryan J Clin Transl Sci Clinical Trial OBJECTIVES/SPECIFIC AIMS: Understand the immunomodulatory effects of anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (G-CSF) on type 1 diabetes patients using samples and in the preclinical model, the nonobese diabetic mouse. METHODS/STUDY POPULATION: Flow cytometry analysis of phase 1 peripheral blood samples treatment of nonobese diabetic mouse with ATG and GCSF and flow cytometry analysis of immune organs (spleen, lymph nodes, blood, bone marrow). RESULTS/ANTICIPATED RESULTS: Changes in both innate and adaptive immune cell subsets including plasmacytoid dendritic cells, naive, memory, effector CD4+ and CD8+ T-cells, and CD4+ T-regulatory cells and CD8+ T-regulatory cells DISCUSSION/SIGNIFICANCE OF IMPACT: Understanding of immune cell targets for immunotherapy in new-onset type 1 diabetes patients. Cambridge University Press 2018-05-10 /pmc/articles/PMC6798906/ http://dx.doi.org/10.1017/cts.2017.136 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Trial
Lin, Andrea
Mathews, Clayton
Haller, Michael
Brusko, Todd
Atkinson, Mark
Flynn, Ryan
2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title_full 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title_fullStr 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title_full_unstemmed 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title_short 2431: Characterization of immune cell differences with anti-thymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in both preclinical and clinical models of type 1 diabetes
title_sort 2431: characterization of immune cell differences with anti-thymocyte globulin (atg) and granulocyte colony stimulating factor (gcsf) in both preclinical and clinical models of type 1 diabetes
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798906/
http://dx.doi.org/10.1017/cts.2017.136
work_keys_str_mv AT linandrea 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes
AT mathewsclayton 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes
AT hallermichael 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes
AT bruskotodd 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes
AT atkinsonmark 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes
AT flynnryan 2431characterizationofimmunecelldifferenceswithantithymocyteglobulinatgandgranulocytecolonystimulatingfactorgcsfinbothpreclinicalandclinicalmodelsoftype1diabetes